Publication:
Long-term prediction of clinical outcomes by the 21-gene test in HR+HER2-breast cancer patients with residual disease after neoadjuvant chemotherapy

Simple item page
dc.conference.dateMAY 03-05, 2022
dc.conference.titleEuropean-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress
dc.contributor.authorPeg, V.
dc.contributor.authorde los Angeles, N.
dc.contributor.authorVieites, B.
dc.contributor.authorBellet, M.
dc.contributor.authorCastilla, C.
dc.contributor.authorGomez Pardo, P.
dc.contributor.authorPerez-Luque, A.
dc.contributor.authorLopez, M. A.
dc.contributor.authorSalvador Bofill, F. J.
dc.contributor.authorAlfaro, L.
dc.contributor.authorPerez Garcia, J. M.
dc.contributor.authorEspinosa-Bravo, M.
dc.contributor.authoraffiliation[Peg, V.] Vall Hebron Univ Hosp, Pathol, Barcelona, Spain
dc.contributor.authoraffiliation[de los Angeles, N.] Hosp Mar Parc Salut Mar, Pathol, Barcelona, Spain
dc.contributor.authoraffiliation[Vieites, B.] Hosp Univ Virgen Rocio, IBIS Inst Biomed Sevilla, Pathol, Seville, Spain
dc.contributor.authoraffiliation[Bellet, M.] Vall Hebron Inst Oncol VHIO, Breast Canc Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Castilla, C.] Hosp Univ Virgen Rocio, Pathol, Seville, Spain
dc.contributor.authoraffiliation[Perez-Luque, A.] Hosp Univ Virgen Rocio, Pathol, Seville, Spain
dc.contributor.authoraffiliation[Lopez, M. A.] Hosp Univ Virgen Rocio, Pathol, Seville, Spain
dc.contributor.authoraffiliation[Salvador Bofill, F. J.] Hosp Univ Virgen Rocio, Pathol, Seville, Spain
dc.contributor.authoraffiliation[Alfaro, L.] Hosp Univ Virgen Rocio, Pathol, Seville, Spain
dc.contributor.authoraffiliation[Gomez Pardo, P.] Vall dHebron Inst Oncol VHIO, Cellex Ctr, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Perez Garcia, J. M.] Ctr Med Teknon, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Espinosa-Bravo, M.] Vall Hebron Univ Hosp, Breast Surg Unit, Barcelona, Spain
dc.date.accessioned2023-05-03T14:40:09Z
dc.date.available2023-05-03T14:40:09Z
dc.date.issued2022-05-05
dc.identifier.doi10.1016/j.annonc.2022.03.118
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422004975/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21903
dc.identifier.wosID792494100104
dc.issue.number3
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.page.numberS171-S172
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleLong-term prediction of clinical outcomes by the 21-gene test in HR+HER2-breast cancer patients with residual disease after neoadjuvant chemotherapy
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
Instituto de Investigación Biomédica de Sevilla (IBIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía